02.10.22
Aptar Pharma, a leader in drug delivery systems, services and active material science solutions, has announced the construction of a new facility in India at a ceremony which also celebrated Aptar Mumbai’s ten year anniversary.
On January 21, 2022, Stephan Tanda, Aptar president and CEO and Kanwal Tikoo, president, India and SEA, Aptar, along with members of Aptar’s executive committee, virtually welcomed Aptar employees who joined from all over the world to witness the groundbreaking of the new facility at Taloja, Mumbai.
Aptar Pharma’s expansion plans in Mumbai will further increase its manufacturing capacity, including the addition of molding capabilities to offer more innovative product solutions to pharma customers in South East Asia.
The new Aptar Mumbai facility is in line with Aptar’s localization strategy and is a direct response to continuing customer demand in the region.
“Over the years, our Pharma business in India has shown robust growth and so, in order to serve the needs of our Indian customers, we are enhancing our manufacturing capabilities. Our new facility is a key step that strengthens our competitive position and brings global technology to India, which will ultimately benefit patients," said Stephan Tanda.
Kanwal Tikoo added, “Aptar Pharma has established market leadership position as a pharma packaging solutions company and we continue to grow our influence in this part of the world as the go-to drug delivery expert. We continue to help our customers succeed and patients to live a better life.”
These sentiments were echoed by Xiangwei Gong, president, Aptar Asia, Gael Touya, president, Aptar Pharma and Alex Theodorakis, president, Aptar Pharma Prescription, who also spoke at the inaugural ceremony and commented on Aptar Pharma’s decade of success in India, which they described as both a key pillar in the pharma ecosystem and a new chapter of growth in the region.
The new Aptar Mumbai facility, which is being built on a 3.5-acre site at the Palava Industrial and Logistics Park at Taloja, Mumbai, will generate further employment opportunities, with construction expected to be completed by Q1, 2023.
On January 21, 2022, Stephan Tanda, Aptar president and CEO and Kanwal Tikoo, president, India and SEA, Aptar, along with members of Aptar’s executive committee, virtually welcomed Aptar employees who joined from all over the world to witness the groundbreaking of the new facility at Taloja, Mumbai.
Aptar Pharma’s expansion plans in Mumbai will further increase its manufacturing capacity, including the addition of molding capabilities to offer more innovative product solutions to pharma customers in South East Asia.
The new Aptar Mumbai facility is in line with Aptar’s localization strategy and is a direct response to continuing customer demand in the region.
“Over the years, our Pharma business in India has shown robust growth and so, in order to serve the needs of our Indian customers, we are enhancing our manufacturing capabilities. Our new facility is a key step that strengthens our competitive position and brings global technology to India, which will ultimately benefit patients," said Stephan Tanda.
Kanwal Tikoo added, “Aptar Pharma has established market leadership position as a pharma packaging solutions company and we continue to grow our influence in this part of the world as the go-to drug delivery expert. We continue to help our customers succeed and patients to live a better life.”
These sentiments were echoed by Xiangwei Gong, president, Aptar Asia, Gael Touya, president, Aptar Pharma and Alex Theodorakis, president, Aptar Pharma Prescription, who also spoke at the inaugural ceremony and commented on Aptar Pharma’s decade of success in India, which they described as both a key pillar in the pharma ecosystem and a new chapter of growth in the region.
The new Aptar Mumbai facility, which is being built on a 3.5-acre site at the Palava Industrial and Logistics Park at Taloja, Mumbai, will generate further employment opportunities, with construction expected to be completed by Q1, 2023.
